Long-term treatment patterns of testosterone replacement medications

Journal of Sexual Medicine

Volumn 11, Issue 8, 2014, Pages 2092-2099

  Donatucci, Craig ^a   Cui, Zhanglin ^a   Fang, Yun ^b   Muram, David ^a  

^a ELI LILLY AND COMPANY   (United States)

^b SYNEOS HEALTH   (United States)

Author keywords

Hypogonadism; Intermittent medication; Testosterone; Utilization patterns

Indexed keywords

DITATE DS; ESTRADIOL CIPIONATE PLUS TESTOSTERONE CIPIONATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE PLUS TESTOSTERONE ENANTATE; TESTOSTERONE; TESTOSTERONE CIPIONATE; TESTOSTERONE ENANTATE; TESTOSTERONE PROPIONATE; UNCLASSIFIED DRUG;

ADULT; AGED; ANDROGEN THERAPY; ARTICLE; DRUG UTILIZATION; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; HYPOGONADISM; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETREATMENT; TREATMENT DURATION;

HYPOGONADISM; INTERMITTENT MEDICATION; TESTOSTERONE; UTILIZATION PATTERNS;

ADMINISTRATION, TOPICAL; ADULT; AGED; ANDROGENS; DRUG ADMINISTRATION SCHEDULE; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; INJECTIONS; LONG-TERM CARE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; QUALITY OF LIFE; TESTOSTERONE; YOUNG ADULT;

EID: 84905058727     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/jsm.12608     Document Type: Article

References (24)

1. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM; Endocrine Society Task Force. Testosterone therapy in adult men with androgen deficiency syndromes: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536-2559.
2. Araujo AB, Esche GR, Kupelian V, O'Donnell AB, Travison TG, Williams RE, Clark RV, McKinlay JB. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab 2007;92:4241-4247.
3. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros J-J, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FCW. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol 2008;159:507-514.
4. Corona G, Rastrelli G, Forti G, Maggi M. Update in testosterone therapy for men. J Sex Med 2011;8:639-654.
5. Corona G, Rastrelli G, Vignozzi L, Maggi M. Emerging medication for the treatment of male hypogonadism. Expert Opin Emerg Drugs 2012;17:239-259.
6. Corona G, Rastrelli G, Maggi M. Diagnosis and treatment of late-onset hypogonadism: Systematic review and meta-analysis of TRT outcomes. Best Pract Res Clin Endocrinol Metab 2013;27:557-579.
7. Food and Drug Administration. Drugs at FDA: FDA approved drug products. 2013. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/080911.pdf (accessed December 16, 2013).
8. CenterWatch. FDA approved drugs for endocrinology. 2013. Available at: http://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/4/endocrinology (accessed December 16, 2013).
9. Baillargeon J, Urban RJ, Ottenbacher KJ, Pierson KS, Goodwin JS. Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Intern Med 2013;173:1465-1466.
10. Handelsman DJ. Global trends in testosterone prescribing, 2000-2011: Expanding the spectrum of prescription drug misuse. Med J Aust 2013;8:548-551.
11. Schoenfeld MJ, Shortridge E, Cui Z, Muram D. Medication adherence and treatment patterns for hypogonadal patients treated with topical testosterone therapy: A retrospective medical claims analysis. J Sex Med 2013;10:1401-1409.
12. Saad F, Aversa A, Isidori AM, Zafalon L, Zitzmann M, Gooren L. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol 2011;165:675-685.
13. Jockenhövel F, Minnemann T, Schubert M, Freude S, Hübler D, Schumann C, Christoph A, Gooren L, Ernst M. Timetable of effects of testosterone administration to hypogonadal men on variables of sex and mood. Aging Male 2009;12:113-118.
14. Rhoden EL, Morgentaler A. Symptomatic response rates to testosterone therapy and the likelihood of completing 12 months of therapy in clinical practice. J Sex Med 2010;7:277-283.
15. Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilinson P; BLAST Study Group. Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: The BLAST study. J Sex Med 2014;11:840-856.
16. Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 2009;15:728-740.
17. Nieschlag E, Cüppers HJ, Wiegelmann W, Wickings EJ. Bioavailability and LH-suppressing effect of different testosterone preparations in normal and hypogonadal men. Horm Res 1976;7:138-145.
18. Jannini EA, Isidori A, Aversa A, Lenzi A, Althof SE. Which is first? The controversial issue of precedence in the treatment of male sexual dysfunctions. J Sex Med 2013;10:2359-2369.
19. Isidori AM, Buvat J, Corona G, Goldstein I, Jannini EA, Lenzi A, Porst H, Salonia A, Traish AM, Maggi M. A critical analysis of the role of testosterone in erectile function: From pathophysiology to treatment-a systematic review. Eur Urol 2014;56:99-112.
20. Francomano D, Ilacqua A, Bruzziches R, Lenzi A, Aversa A. Effects of 5-year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome. Urology 2014;83:167-174.
21. Yassin AA, Doros G. Testosterone therapy in hypogonadal men results in sustained and clinically meaningful weight loss. Clin Obes 2013;3:73-83.
22. Traish AM, Haider A, Doros G, Saad F. Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: An observational, long-term registry study. Int J Clin Pract 2014;68:314-329.
23. Saad F, Haider A, Doros G, Traish A. Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss. Obesity 2013;21:1975-1981.
24. Schwarz LM, Woloshin S. Low "T" as in "Template": how to sell disease. JAMA Intern Med 2013;173:1458-1460.